A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity - Trial NCT06411730
Access comprehensive clinical trial information for NCT06411730 through Pure Global AI's free database. This Phase 1 trial is sponsored by Celgene and is currently Not yet recruiting. The study focuses on Healthy Participants. Target enrollment is 64 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Celgene
Timeline & Enrollment
Phase 1
May 14, 2024
Oct 08, 2024
Primary Outcome
Number of participants with adverse events (AEs),Number of participants with serious adverse events (SAEs),Number of participants with vital sign (VS) abnormalities,Number of participants with physical examination abnormalities,Number of participants with electrocardiogram (ECG) abnormalities,Number of participants with clinical laboratory asssement abnormalities,Number of participants with treatment-emergent suicidal ideation and behavior through assessment of Columbia Suicide Severity Rating Scale (C-SSRS)
Summary
The purpose of this study is to evaluate the safety, tolerability, and drug levels of orally
 administered BMS-986368 in healthy participants, healthy elderly participants, and healthy
 participants of japanese ethnicity.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06411730
Non-Device Trial